AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AMGEN INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$424.94−7.55 (-1.75%)
Close on Oct 19, 2026
- Market cap
- $231.17B
- P/E (TTM)
- 26.4
- Dividend yield
- 2.27%
AMGEN INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $9.54B | $8.22B | $9.37B | $9.14B | $8.77B | $7.87B | $8.72B | $8.15B | $8.04B | $7.12B | $7.83B | $6.55B | 94.9% | +8.7% |
| Other products | $1.70B | $1.53B | $2.07B | $1.85B | $1.38B | $1.48B | $1.57B | $1.36B | $1.33B | $1.37B | $1.38B | $1.00B | 16.9% | +23.0% |
| Repatha | $953.00M | $876.00M | – | $794.00M | $696.00M | $656.00M | $606.00M | $567.00M | $532.00M | $517.00M | $417.00M | $406.00M | 9.5% | +36.9% |
| Prolia | $759.00M | $727.00M | $1.05B | $1.14B | $1.12B | $1.10B | $1.17B | $1.05B | $1.17B | $999.00M | $1.11B | $986.00M | 7.5% | -32.4% |
| EVENITY | $714.00M | $562.00M | $599.00M | $541.00M | $518.00M | $442.00M | $431.00M | $399.00M | $391.00M | $342.00M | $318.00M | $307.00M | 7.1% | +37.8% |
| ENBREL | $580.00M | $320.00M | $532.00M | $580.00M | $604.00M | $510.00M | $1.02B | $825.00M | $909.00M | $567.00M | $1.02B | $1.04B | 5.8% | -4.0% |
| TEPEZZA | $576.00M | $490.00M | $457.00M | $560.00M | $505.00M | $381.00M | $460.00M | $488.00M | $479.00M | $424.00M | $448.00M | $0 | 5.7% | +14.1% |
| Other revenues | $517.00M | $400.00M | $499.00M | $420.00M | $408.00M | $276.00M | $370.00M | $352.00M | $347.00M | $329.00M | $363.00M | $355.00M | 5.1% | +26.7% |
| Otezla | $491.00M | $431.00M | $625.00M | $585.00M | $618.00M | $437.00M | $624.00M | $564.00M | $544.00M | $394.00M | $629.00M | $567.00M | 4.9% | -20.6% |
| TEZSPIRE | $486.00M | $343.00M | $474.00M | $377.00M | $342.00M | $285.00M | $296.00M | $269.00M | $234.00M | $173.00M | $177.00M | $161.00M | 4.8% | +42.1% |
| BLINCYTO | $472.00M | $415.00M | $413.00M | $392.00M | $384.00M | $370.00M | $381.00M | $327.00M | $264.00M | $244.00M | $241.00M | $220.00M | 4.7% | +22.9% |
| Nplate | $430.00M | $412.00M | $385.00M | $457.00M | $369.00M | $313.00M | $337.00M | $456.00M | $346.00M | $317.00M | $386.00M | $419.00M | 4.3% | +16.5% |
| KRYSTEXXA | $400.00M | $255.00M | $435.00M | $320.00M | $349.00M | $236.00M | $346.00M | $310.00M | $294.00M | $235.00M | $272.00M | $0 | 4.0% | +14.6% |
| Aranesp | $352.00M | $311.00M | $333.00M | $357.00M | $359.00M | $340.00M | $308.00M | $337.00M | $348.00M | $349.00M | $319.00M | $323.00M | 3.5% | -1.9% |
| XGEVA | $352.00M | $411.00M | $447.00M | $539.00M | $532.00M | $566.00M | $561.00M | $541.00M | $562.00M | $561.00M | $527.00M | $519.00M | 3.5% | -33.8% |
| Vectibix | $338.00M | $287.00M | $319.00M | $284.00M | $305.00M | $267.00M | $246.00M | $282.00M | $270.00M | $247.00M | $251.00M | $252.00M | 3.4% | +10.8% |
| UPLIZNA | $335.00M | $262.00M | – | – | $176.00M | $91.00M | – | – | – | – | – | – | 3.3% | +90.3% |
| KYPROLIS | $314.00M | $330.00M | – | $359.00M | $378.00M | $324.00M | $372.00M | $378.00M | $377.00M | $376.00M | $350.00M | $349.00M | 3.1% | -16.9% |
| IMDELLTRA/IMDYLLTRA | $288.00M | $258.00M | – | – | $134.00M | $81.00M | – | – | – | – | – | – | 2.9% | +114.9% |
By region
From the segment and revenue-disaggregation notes of Amgen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.